News 8/16

top of page

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

ipharmaservices

Sep 24, 2020

ESMO 2020

ESMO 2020

ESMO 2020

ipharmaservices

Sep 19, 2020

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

ipharmaservices

Sep 18, 2020

Novartis Beovu demonstrated non-inferiority vs. aflibercept in the PEP and superiority in SEP

Novartis Beovu demonstrated non-inferiority vs. aflibercept in the PEP and superiority in SEP

Novartis Beovu demonstrated non-inferiority vs. aflibercept in the PEP and superiority in SEP

ipharmaservices

Sep 14, 2020

MSVirtual2020: Novartis and Roche, two Swiss giants, presents robust trial results of their assets

MSVirtual2020: Novartis and Roche, two Swiss giants, presents robust trial results of their assets

MSVirtual2020: Novartis and Roche, two Swiss giants, presents robust trial results of their assets

ipharmaservices

Sep 11, 2020

Merck announced trial results of gefapixant in patients with refractory or unexplained chronic cough

Merck announced trial results of gefapixant in patients with refractory or unexplained chronic cough

Merck announced trial results of gefapixant in patients with refractory or unexplained chronic cough

ipharmaservices

Sep 11, 2020

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

ipharmaservices

Sep 10, 2020

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

ipharmaservices

Sep 9, 2020

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

ipharmaservices

Sep 7, 2020

Gene therapy developer AveXis renamed as Novartis Gene Therapies

Gene therapy developer AveXis renamed as Novartis Gene Therapies

Gene therapy developer AveXis renamed as Novartis Gene Therapies

ipharmaservices

Sep 5, 2020

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA extended emergency use authorization of Veklury to all hospitalized patients

ipharmaservices

Aug 30, 2020

Bayer submitted vericiguat for market authorization in China

Bayer submitted vericiguat for market authorization in China

Bayer submitted vericiguat for market authorization in China

ipharmaservices

Aug 28, 2020

Bayer’s Xofigo received approval for prostate cancer in China

Bayer’s Xofigo received approval for prostate cancer in China

Bayer’s Xofigo received approval for prostate cancer in China

ipharmaservices

Aug 27, 2020

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

ipharmaservices

Aug 27, 2020

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

ipharmaservices

Aug 27, 2020

Novartis presented robust clinical trial data of asciminib for chronic myeloid leukemia

Novartis presented robust clinical trial data of asciminib for chronic myeloid leukemia

Novartis presented robust clinical trial data of asciminib for chronic myeloid leukemia

ipharmaservices

Aug 26, 2020

BMS announced to acquire Forbius, targets to strengthen oncology and fibrosis portfolio

BMS announced to acquire Forbius, targets to strengthen oncology and fibrosis portfolio

BMS announced to acquire Forbius, targets to strengthen oncology and fibrosis portfolio

ipharmaservices

Aug 26, 2020

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

ipharmaservices

Aug 25, 2020

Merck’s Keytruda received one more indication and dosage form approval in Japan

Merck’s Keytruda received one more indication and dosage form approval in Japan

Merck’s Keytruda received one more indication and dosage form approval in Japan

ipharmaservices

Aug 25, 2020

Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

ipharmaservices

Aug 23, 2020

bottom of page